About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 226 blog entries.

Intellia continues to advance in vivo candidate

2022-05-09T21:22:59+02:00May 9, 2022|HAEi News|

At the Intellia Therapeutics, Inc. operational highlights and financial results for the first quarter ended 31 March 2022, President and CEO John Leonard, M.D., says: “We continue to advance our second in vivo candidate, NTLA-2002, which benefits from the modularity of our platform. We look forward to another important clinical milestone in the second half of [...]

Strong patient demand for ORLADEYO

2022-05-06T10:41:35+02:00May 6, 2022|HAEi News|

From the BioCryst Pharmaceuticals, Inc. financial results for the first quarter ended 31 March 2022: “We are now over a year into the ORLADEYO launch and are excited to see strong and continuing patient demand and steady expansion in our prescriber base among both new and existing prescribers. These trends continued in the first quarter [...]

Héma-Québec has awarded a two-year tender for TAKHZYRO®

2022-04-30T20:19:34+02:00April 29, 2022|HAEi News|

Héma-Québec has awarded a two-year tender for TAKHZYRO® (lanadelumab injection) as the sole option for prophylaxis subcutaneous treatment for type I/II HAE patients. The two-year term which began 1 April 2022, includes the option for Héma-Québec to extend the tender for an additional two years. “My team and I took part in the clinical trials [...]

TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for HAE Patients in the United States

2022-04-19T08:42:57+02:00April 19, 2022|HAEi News|

TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of HAE in adult and pediatric patients 12 years of age and older. Approved by the U.S. Food and Drug Administration on 8 February 2022, the TAKHZYRO prefilled syringe is ready to use and requires fewer preparation steps than the single-dose [...]

TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met its Objectives

2022-04-19T08:33:06+02:00April 19, 2022|HAEi News|

The Phase 3 SHP643-301 study evaluating the safety profile and pharmacokinetics of TAKHZYRO® (lanadelumab) in patients 2 to <12 years of age is complete and has met its objectives. The safety profile was consistent with that seen in the clinical program for patients 12 years of age and older; there were no serious adverse events [...]

Orchard sees promising early-stage research in HSC gene therapy

2022-04-07T21:12:02+02:00March 31, 2022|HAEi News|

At the presentation of the financial results for the quarter and year ended 31 December 2021, Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., says that a promising early-stage research program that apply a hematopoietic stem cell (HSC) gene therapy approach in HAE will remain an important part of the portfolio going forward given the promise [...]

Pharvaris looking forward to next milestones

2022-04-07T21:06:16+02:00March 30, 2022|HAEi News|

At the presentation of the company’s financial results for the fourth quarter and year ended 31 December 2021, Pharvaris CEO Berndt Modig says: “The time since our initial public offering in February 2021 has been transformational for Pharvaris, enabling us to reach clinical development milestones. We look forward to our next milestones and will continue [...]

HAE patient presents bad news-good news story

2022-04-07T20:58:03+02:00March 30, 2022|HAEi News|

Early in the pandemic, HAE patient Scott McCoy described his encounter with COVID-19 in a webinar for US HAEA. It was a bad news-good news story. The bad news was that McCoy had become infected with the novel coronavirus prior to vaccines being available. But the good news was that his infection did not cause [...]

Takeda presents abstracts on study of TAKHZYRO®

2022-04-07T20:54:06+02:00March 30, 2022|HAEi News|

At the American Academy of Allergy, Asthma and Immunology (AAAAI) 78th Annual Meeting Takeda presents four abstracts including interim real-world data from the observational Phase 4 EMPOWER study of TAKHZYRO® (lanadelumab) as a treatment for people with HAE Type I or II in North America, as well as findings from a post-hoc analysis of the [...]

TAKHZYRO® approved in Japan

2022-04-07T20:50:46+02:00March 29, 2022|HAEi News|

Takeda has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelumab) subcutaneous injection 300mg syringes for prophylaxis against acute attacks of HAE in adult and pediatric patients 12 years of age and older in Japan. This approval is primarily based on results of the global Phase 3 HELP (Hereditary Angioedema [...]

Go to Top